Epsilogen is the world’s leading pan-isotype antibody therapeutic company for the treatment of cancer
Our unique and proprietary expertise is focused on the discovery and development of immunoglobulin IgE, IgA and IgG-based therapeutics. The immune system relies upon the differential effector functions of the various antibody isotypes to generate the best immune response to a given challenge. Similarly, we match the attributes of each isotype to a given cancer to optimize performance. We have also combined different isotypes into single antibody molecules to broaden and strengthen their anti-cancer potential.
Our lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic. It targets folate receptor ⍺ and was found to be safe and well tolerated in a phase I study with early signs of clinical activity. A phase Ib study in platinum-resistant ovarian cancer patients is now underway.
IgE
IgE is ideal for the treatment of solid tumours with enhanced tumour access, long tissue half-life and ability to kill cancer cells expressing very low levels of antigen. It activates both myeloid cells and T cells, warming up the tumour micro-environment, and can combine well with checkpoint inhibitors.
MOv18 IgE
MOv18 IgE is our lead clinical candidate and the world’s first IgE therapeutic to enter the clinic. It is currently in a phase Ib study in platinum-resistant ovarian cancer (PROC).
IgA
IgA’s anti-cancer potential is mediated by the activation of neutrophils, highly abundant effector cells which drive innate and adaptive immunity.
News
Join our pioneering team
The opportunity to contribute to the innovation of all aspects of the company’s pipeline and platforms.